nabumetone nonsteroidal antiinflammatory drug nabumetone developed beecham first received regulatory approval available numerous brand names relafen relifex gambaran nabumetone nonacidic nsaid prodrug rapidly metabolized liver active metabolite acetic acid nabumetones active metabolite inhibits cyclooxygenase enzyme preferentially blocks activity indirectly responsible production inflammation pain arthritis active metabolite nabumetone felt compound primarily responsible therapeutic effect comparatively parent drug poor inhibitor byproducts particularly prostaglandins may less nephrotoxic two known polymorphs nabumetone little effect renal prostaglandin secretion less association heart failure traditional drugs effects nabumetone blood pressure control hypertensive patients ace inhibitors also goodclarification needed equivalent nabumetone used treat pain inflammationcitation needed shown slightly lower risk gastrointestinal side effects nonselective nsaids since nonacidic prodrug metabolized active acid formcitation needed side effects include bloody black tarry stools change color frequency amount urine chest pain shortness breath coughing blood pale stools numbness weakness flulike symptoms leg pain vision problems speech problems problems walking weight gain stomach pain cold sweat skin rash blisters headache swelling bleeding bruising vomiting blood jaundice diarrhea constipation dizziness indigestion gas nausea ringing october us food drug administration fda required drug label updated nonsteroidal antiinflammatory medications describe risk kidney problems unborn babies result low amniotic recommend avoiding nsaids pregnant women weeks later httpsenwikipediaorgwikinabumetone